TEVANYSEPharmaceutical PreparationsFiscal year ends December 31

TEVA PHARMACEUTICAL INDUSTRIES LTD

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 29, 2026

$41.31−0.19 (-0.46%)

Close on Oct 19, 2026

Community

Notes and questions about Teva Pharmaceutical Industries from other investors

Discussion opens with sign-in. Posts will be able to point at any number on these pages, so everyone sees exactly which figure is being discussed.

Parsed from the XBRL in Teva Pharmaceutical Industries's annual and quarterly filings with the SEC
Per-share figures adjusted for the 2-for-1 split on Jul 1, 2004
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is TEVA.

Revenue growth-15.2% · median 9.3%

Gross margin64.4% · median 37.1%

Operating margin11.4% · median 11.3%

Net margin5.0% · median 5.0%

Advertisement
300 × 250